Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil an… Read more
Nectar Lifesciences Limited (NECLIFE) - Total Assets
Latest total assets as of September 2025: ₹18.15 Billion INR
Based on the latest financial reports, Nectar Lifesciences Limited (NECLIFE) holds total assets worth ₹18.15 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nectar Lifesciences Limited - Total Assets Trend (2006–2025)
This chart illustrates how Nectar Lifesciences Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nectar Lifesciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Nectar Lifesciences Limited's total assets of ₹18.15 Billion consist of 60.5% current assets and 39.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.9% |
| Accounts Receivable | ₹3.46 Billion | 16.9% |
| Inventory | ₹6.90 Billion | 33.7% |
| Property, Plant & Equipment | ₹6.33 Billion | 30.9% |
| Intangible Assets | ₹565.04 Million | 2.8% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Nectar Lifesciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nectar Lifesciences Limited's current assets represent 60.5% of total assets in 2025, a decrease from 66.4% in 2006.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2025, down from 5.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 33.7% of total assets.
Nectar Lifesciences Limited Competitors by Total Assets
Key competitors of Nectar Lifesciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Nectar Lifesciences Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Nectar Lifesciences Limited generates 0.82x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nectar Lifesciences Limited is currently not profitable relative to its asset base.
Nectar Lifesciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.36 | 1.31 | 1.28 |
| Quick Ratio | 0.36 | 0.56 | 0.52 |
| Cash Ratio | 0.01 | 0.02 | 0.00 |
| Working Capital | ₹-4.54 Billion | ₹ 3.08 Billion | ₹ 3.36 Billion |
Nectar Lifesciences Limited - Advanced Valuation Insights
This section examines the relationship between Nectar Lifesciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.31 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | ₹20.47 Billion |
| Market Capitalization | $14.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nectar Lifesciences Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nectar Lifesciences Limited's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nectar Lifesciences Limited (2006–2025)
The table below shows the annual total assets of Nectar Lifesciences Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹20.47 Billion | -6.56% |
| 2024-03-31 | ₹21.91 Billion | +0.08% |
| 2023-03-31 | ₹21.89 Billion | -8.43% |
| 2022-03-31 | ₹23.91 Billion | -3.25% |
| 2021-03-31 | ₹24.71 Billion | -6.16% |
| 2020-03-31 | ₹26.33 Billion | -2.65% |
| 2019-03-31 | ₹27.05 Billion | -0.69% |
| 2018-03-31 | ₹27.24 Billion | +5.54% |
| 2017-03-31 | ₹25.81 Billion | +0.96% |
| 2016-03-31 | ₹25.56 Billion | +1.83% |
| 2015-03-31 | ₹25.10 Billion | +4.86% |
| 2014-03-31 | ₹23.94 Billion | +5.28% |
| 2013-03-31 | ₹22.74 Billion | +7.22% |
| 2012-03-31 | ₹21.21 Billion | +17.01% |
| 2011-03-31 | ₹18.13 Billion | +22.43% |
| 2010-03-31 | ₹14.80 Billion | +15.16% |
| 2009-03-31 | ₹12.86 Billion | +35.54% |
| 2008-03-31 | ₹9.49 Billion | +22.06% |
| 2007-03-31 | ₹7.77 Billion | +69.91% |
| 2006-03-31 | ₹4.57 Billion | -- |